Market cap
$468 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 27.50 | 20.55 | -22.90 | -30.13 | -232.28 |
| Net Profit | 27.52 | 11.38 | -21.42 | -23.78 | -236.18 |
| EPS | 28.30 | 7.28 | -29.71 | -28.98 | -241.27 |
| Book Value | -- | -- | -32.15 | -22.90 | -10.53 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -14.30 | -- | -- | -- |
| Net Margin
| -- | 34.47 | -- | -- | -- |
| Return on equity
| -33.65 | -19.77 | -68.93 | -44.34 | -33.88 |
| Return on Capital
| -33.52 | -19.68 | -- | -44.18 | -33.74 |
| Return on Assets
| -31.31 | -19.05 | -49.18 | -40.61 | -31.78 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
-44.18
|
-33.74
|
-22.64
|
-17.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-68.93
Lower than Peers by 28.60
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-68.93
|
-44.34
|
-33.88
|
-22.74
|
-17.16
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-49.18
Lower than Peers by 17.94
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-49.18
|
-40.61
|
-31.78
|
-21.55
|
-16.10
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
-67.98
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
-60.31
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
-1.00
|
-0.45
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-22.90
Lower than Peers by 21.88
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-22.90
|
-24.43
|
-10.17
|
8.14
|
-194.42
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-21.42
Lower than Peers by 13.89
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-21.42
|
5.96
|
-23.85
|
-17.30
|
-195.64
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-29.71
Lower than Peers by 43.94
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-29.71
|
-0.02
|
-0.22
|
-0.17
|
-2.00
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-41.39
Lower than Peers by 31.26
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-41.39
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
8.13
Higher than Peers by 2.32
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
8.13
|
7.82
|
24.85
|
18.24
|
35.77
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
8.13
Higher than Peers by 2.43
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
8.13
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
-11.72
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
0.27
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
7,639.96
|
19.08
|
17.73
|
4,976.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
-1.76
|
-1.68
|
-1.87
|
-3.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.16
Lower than Peers by 3.17
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
2.16
|
1.01
|
0.64
|
0.46
|
0.63
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-260.47
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
-260.47
|
0.13
|
1.29
|
2.69
|
5.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
468
Higher than Peers by 326
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Atea Pharmaceuticals (AVIR)
|
468
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|